2012-11-08 20:24:18 -

U.S. stocks extended losses on Thursday, with the Nasdaq briefly dropping 1
percent, as investors recalibrated for upcoming negotiations over the "fiscal
cliff," which overshadowed a batch of positive economic data. Investors worry
that if no deal is reached in Congress over some $600 billion in spending cuts
and tax increases due to kick in early next year, it could derail the U.S.
economic recovery and lead to a recession. Following are the notable movers at
mid day on Thursday:-

DUSA Pharmaceuticals, Inc. (NASDAQ: DUSA) shares climbed 37.72% to $7.96 in the
early hour. Block & Leviton LLP announced that it has commenced an investigation
into possible breaches of fiduciary duties by the Board of Directors of DUSA
Pharmaceuticals Inc. (DUSA or the Company) with regards to the proposed
acquisition of   the Company by Sun Pharmaceutical Industries Ltd. (Sun) in a cash
transaction announced November 8, 2012. Under the terms of the agreement, Sun
will acquire DUSA in a cash tender offer for approximately $8.00 per share.

Tekmira Pharmaceuticals (Nasdaq: TKMR) (TSX: TKM) surged over 15%  to a mid-day
high of $5.19 in anticipation of the firm's November 14(th) court date against
Alnylam Pharmaceuticals (ALNY). A report filed by Doug Macron of GenomeWeb's
Gene Silencing News helped fuel the rally by revealing that Alnylam was
estimating damages in the Tekmira Suit could reach $1.5 billion.

InterMune, Inc.(NASDAQ: ITMN) shares gained 15.63% to $9.44 after the company
reported third-quarter net loss of $45.4 million or $0.70 per share, as compared
to $38.2 million or $0.63 per share in the same quarter last year. Total
revenues for the quarter rose to $7.5 million from $0.1 million in the
comparable quarter last year. Analysts expected a loss of $0.84 per share on
revenues of $6.16 million.

BioScrip Inc.(NASDAQ: BIOS) shares climbed 12.77% to $9.98 in the early hour.
The company announced 2012 third quarter financial results. Third quarter
revenue from continuing operations were $170.4 million and the net loss from
continuing operations was $0.6 million, or $0.01 per diluted share. Consolidated
Adjusted EBITDA for the third quarter was $11.6 million versus $11.7 million for
the third quarter of 2011.

Repligen Corporation (NASDAQ: RGEN) shares climbed 8.63% to $5.41 after the
company reported net income for the three-month period ended September 30, 2012
of $1,806,000 or $0.06 per diluted share, as compared to $605,000 or $0.02 per
diluted share for the same period in 2011, an increase of 199%. Total revenue
was $15,104,000, as compared to $8,631,000 for the same period in 2011, an
increase of 75%.

OraSure Technologies, Inc. (OSUR) stock fell 14.09% to $7.43 after the company's
consolidated revenues were $22.1 million for the third quarter of 2012, a 2%
increase from the comparable quarter of 2011. Consolidated net loss for the
third quarter of 2012 was $2.4 million, or $0.04 per share, which compares to a
net loss of $3.9 million, or $0.08 per share, for the third quarter of 2011.




Content & Media Contact: newseditor@equitybrief.net




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Equity Brief via Thomson Reuters ONE
[HUG#1656489]